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ABSTRACT
Squamous cell carcinoma of the anorectal canal (SCCA) is a rare HPV-related 
malignancy that is steadily increasing in incidence. A high unmet need exists for 
patients with persistent loco-regional and metastatic disease. Axalimogene filolisbac 
(ADXS11-001) is an investigational immunotherapy that stimulates tumor-specific 
responses against HPV-associated cancers, and has demonstrated benefit in 
metastatic cervical cancer. We conducted this single-arm, multicenter, phase 2 trial 
in patients with persistent/recurrent, loco-regional or metastatic SCCA. Patients 
received ADXS11-001, 1 × 109 colony-forming units intravenously every 3 weeks. 
A Simon 2-stage design was used to test primary co-endpoints of overall response 
rate (ORR) and 6-month progression-free survival (PFS) rate. Study would proceed 
to full enrollment if ORR ≥ 10% or 6-month PFS rate ≥ 20%. Thirty-six patients were 
treated; 29 patients were evaluable for response. One patient had a prolonged partial 
response (3.4% ORR). The 6-month PFS rate was 15.5%. Grade 3 adverse event 
were noted in 10 patients, with the majority being cytokine-release symptoms; one 
grade 4 adverse event was noted. No grade 5 adverse events occurred. ADXS11-001 
was safe and well-tolerated in patients with SCCA. However, this study did not meet 
either primary endpoint. ADXS11-001 may be more beneficial when administered in 
combination with other cytotoxic or targeted agents.
INTRODUCTION
It is estimated that approximately 8600 new cases of 
anal cancer will be diagnosed in the United States in 2019, 
and 1160 people will die from the disease [1, 2]. Although 
accounting for less than 1% of all malignancies, anal 
cancer has been increasing in incidence by 2.2% per year 
for the past decade, while annual death rates increased by 
2.9% per year from 2005 to 2014 [1]. Primary tumors of 
the anal canal can be of multiple types, with squamous cell 
carcinoma of the anal canal (SCCA) comprising the most 
common histology (85%), followed by adenocarcinoma 
(10%) [3]. Most patients with localized SCCA (stage 
I-III) can be cured by chemoradiation [4, 5], however up 
to 25% of patients develop distant metastases (Stage IV 
disease) [6, 7]. Patients with Stage IV disease have dismal 
prognoses, with 5-year survival rates of 15–20% [8]. 
Limited prospective trials have been completed in 
patients with metastatic disease due to the rarity of the 
disease.  A single arm phase II trial of docetaxel, cisplatin, 
and 5-fluoruracil (5-FU) in treatment naïve patients 
resulted an impressive response rate of 89% [9].  A small 
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randomized phase II trial compared 5-FU plus cisplatin 
vs. carboplatin plus paclitaxel noting equivalent response 
rates of 57% vs. 59%, respectively [10]. 
The most common risk factor for anal cancer is 
infection with human papilloma virus (HPV), which is 
found in more than 90% of anal cancer cases [11–14]. The 
HPV proteins E6 and E7 play central roles in transforming 
anal squamous epithelium into invasive cancer [15–17], 
are immunogenic, and may trigger an anti-tumor immune 
response by recruitment of tumor-infiltrating lymphocytes 
[18, 19]. Given the immunogenicity associated with these 
tumors, a recent single-arm phase II study of patients 
with previously-treated metastatic SCCA examined the 
response rate and safety of nivolumab, an anti-PD-1 
antibody that boosts antitumor immunity by diminishing 
immune checkpoint activity [20]. Among 37 patients, the 
overall response rate (ORR) was 24% [95% confidence 
interval [CI]: 15%–33%]) with an observed prolonged 
complete response (CR) in one patient longer than 2 
years. The median progression-free survival (PFS) was 
4.1 months (95% CI 3.0–7.9 months) and 6-month PFS 
was 38% (95% CI: 24%–60%). A Phase IB study with 
pembrolizumab found similar benefit in patients with 
PD-L1 overexpressing unresectable anal cancer, with an 
ORR of 17% [95% CI: 5%–37%] and median PFS of 3.0 
months [95% CI: 1.7–7.3 months]) [21]. Based on these 
promising results, nivolumab and pembrolizumab are 
currently recommended as treatment options in previously 
treated patients with metastatic anal cancer [22]. While 
these two encouraging studies illustrate the potential 
benefits of immunotherapy in patients with recurrent or 
metastatic anal cancer there is still a need for additional 
therapies to treat this orphan disease. 
Axalimogene filolisbac (ADXS11-001) is a new 
immunotherapeutic agent for HPV-associated locally 
advanced cancers [23, 24].  This novel agent consists 
of a live, irreversibly-attenuated (prfA-deficient), and 
nonpathogenic strain of the intracellular bacterium Listeria 
monocytogenes (Lm), which has been bioengineered 
to secrete an antigen-adjuvant fusion protein between 
Listeriolysin O (LLO) and the HPV-16 E7 oncoprotein [23, 
24]. Preclinical studies found that ADXS11-001 stimulated 
tumor-specific responses against HPV-associated cancers 
by stimulating the innate, adaptive and humoral arms 
of the immune system. Furthermore, treatment reduced 
immune tolerance by neutralizing regulatory T-cells 
and myeloid-derived suppressor cells within the tumor 
microenvironment [25–34].  In a single institution pilot 
study, ADXS11-001 was evaluated in combination with 
radiation and chemotherapy in locally advanced high-
risk anal cancer (T>4 cm and/or lymphadenopathy). All 
9 assessable patients had complete clinical responses 
of the primary tumor at six months. Eight of 9 patients 
(89%) were progression-free after a median follow-up of 
42 months [35]. ADXS11-001 has also shown clinically 
meaningful responses in patients with recurrent metastatic 
cervical cancer and is being evaluated in an ongoing phase 
III clinical trial, NCT02853604 [36, 37]. We report here 
the first-in-human study to assess tumor response and 
safety of ADXS11-001 in patients with previously treated 
advanced SCCA.
RESULTS
Thirty-nine patients were screened from May 2016 
to December 2016; three patients were screen failures. 
Data cut-off date was August 15, 2017. Thirty-six patients 
were evaluable for the safety analysis; 29 patients were 
evaluable for response based on diagnostic imaging. Seven 
patients withdrew from the study prior to receiving cycle 2 
of therapy; 5 patients had clinical progression (3 patients 
within one week of initiating therapy); 1 patient developed 
a grade 3 treatment related infusion reaction; and 1 patient 
was lost to follow-up. Baseline demographic data are 
listed in Table 1. Prior treatment included chemotherapy 
in 34 patients (94.4%) and chemoradiation in 26 patients 
(72.2%) (Table 1). The median follow-up time for all 
patients was 8.1 (range 1.3 to 17.9) months. Patients were 
treated for a median of 9 weeks (one treatment cycle: 
range 1–6) and received a median of 3 doses of ADXS-11-
001 (range 1–21, interquartile range 3–5). At the time of 
the data cut-off, 36 patients had discontinued treatment by 
meeting a protocol-specified criterion: 27 patients (75%) 
due to disease progression, 2 patients (5.6%) withdrew 
consent, investigator withdrew 2 patients (5.6%), and 4 
patients (11.1%) discontinued due to an adverse event 
(Figure 1). Treatment remains ongoing for 1 patient as of 
February 16, 2018. 
In Stage I of the study, 1 patient achieved a partial 
response (PR; ORR 3.4%; Table 2) with a duration of 
6.0 months, and a maximum decrease in size of target 
lesions by 83%. Six patients had stable disease (SD; 
20.7%) with all of these patients meeting the definition 
of disease control by maintaining response for at least 24 
weeks. Twenty patients (55.6%) had disease progression 
at initial restaging. The 6-month PFS was 15.5% (95% CI 
5.7–29.6%). The median PFS (Figure 2) was 2.0 months 
(95% CI 1.8–2.1 mos.) with a median OS (Figure 3) of 
12.6 mos. (95% CI 5.4–Not Estimable). 
Toxicities
Of the 36 patients treated with ADXS11-001, the 
most common treatment-related adverse events occurring 
in ≥ 25% of patients were chills, pyrexia, nausea, 
hypotension, vomiting, fatigue, and headache (Table 3). 
Grade 3 treatment-related adverse events occurred in 
10 patients (27.8%); 1 patient each had cytokine release 
syndrome, ascites, diarrhea, encephalopathy, and acute 
renal failure; two patients each had an infusion-related 
reaction, dyspnea, and increased hepatic enzymes; and 4 
patients had hypotension.  One patient (2.8%) had a Grade 
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4 treatment-related adverse events of respiratory failure. 
(Table 3). There were no treatment-related deaths (Table 3). 
Five patients discontinued the study because of drug-
related toxicity. There were no cases of delayed listeria 
infection during the Lm surveillance monitoring period.
DISCUSSION
This study was prospectively designed to evaluate 
ADXS11-001 in patients who had received previous 
treatment for refractory metastatic SCCA. There are a 
limited number of treatment options available for this 
population. Historically, doublet chemotherapy with 
cisplatin and fluorouracil was recognized as the most 
common treatment provided for treatment naïve patients. 
The previously conducted studies of immune checkpoint 
inhibitors in this population demonstrated findings which 
are encouraging with respect to providing meaningful 
clinical benefit for these patients [40]. However, the need 
for novel treatments still remains.  
Table 1: Demographics and baseline characteristics
All Treated (n = 36)
Median age, years (range) 60.5 (43, 77)
Female gender, n (%) 29 (80.6)
Race, n (%)
 Asian 2 (5.6)
 Black or African American 1 (2.8)
 White 32 (88.9)
 American Indian or Alaskan Native 1 (2.8)
ECOG performance status, n (%)
 0 25 (69.4)
 1 11 (30.6)
Time from initial diagnosis to first dose (N = 28)
 Median time, months (range) 29.7 (9, 201)
Tumor stage at entry, n (%)
 II 1 (2.8)
 IIA 0
 IIB 1 (2.8)
 III 2 (5.6)
 IIIA 0
 IIIB 0
 IV 29 (80.6)
 Other 3 (8.3)
Prior cancer surgery, n (%)
 Yes 22 (61.1)
 No 14 (38.9)
Prior therapy, n (%)
 Any 35 (97.2)
 Chemotherapy 34 (94.4)
 Immunotherapy 10 (27.8)
Number of prior regimens, n (%)
 1 2 (5.6)
 2 6 (16.7)
 3 7 (19.4)
 ≥ 4 20 (55.6)
ECOG, Eastern Cooperative Oncology Group.
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Although our multicenter phase II study, did not 
fulfill the primary endpoint of greater than 20% PFS, there 
are advantages to this clinical analysis.  This is the first, 
multicenter trial of a novel bioengineered vaccine that 
we are aware of specific to HPV16/E7.  Furthermore, a 
durable PR was achieved in a patient who had previously 
failed immune checkpoint inhibitor inhibition. In addition, 
ADXS11-001 was well-tolerated with a safety profile 
consistent with what has been reported in other HPV-
associated malignancies [24]. The median OS, measured 
from the time of the first treatment, was 12.6 months. 





 CR 0 (0)
 PR 1 (3.4)
 SD 6 (20.7)
 PD 20 (69.0)
 NE 2 (6.9)
ORR, % (95% CI)c 3.4 (0, 17.8)
DCR, % (95% CI) d 24.1 (10.3, 24.5)
Median PFS, months (95% CI) 2.0 (1.8, 2.1)
CI, confidence interval; CR, complete response; DCR, disease control rate; NE, not evaluable; ORR, overall response rate. 
PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease.
aAll enrolled patients who had at least one post-baseline tumor assessment.
bBest overall responses were identical with or without response confirmation.
cORR = (CR + PR)/total × 100.
dDCR = (CR + PR + SD)/total × 100.
Figure 1: Consort flow diagram. aSafety population: all patients who received at least one dose of ADXS11-001 (note: all 36 enrolled 
patients received at least one dose). bEfficacy population: all patients who received at least one dose of ADXS11-011 and had at least one 
post-baseline tumor response assessment. Note: 31 patients were planned for Stage 1 but patients consented at the time of the 31st patient 
were allowed to enroll, leading to 5 additional patients.
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study, with a median OS of 11.5 months (95% CI 7.1–not 
estimable) [40]. It is likely that ADXS11-001 would likely 
work better in combination with other treatments, such as 
immune checkpoint blockade agents given their promising 
single agent results in this patient population [20, 21], but 
future clinical studies are needed for confirmation. 
There were several limitations in this study. 
This was a small single arm phase II study of which 5 
patients had very early evidence of clinical progression 
and were unevaluable by diagnostic imaging. Second, 
due to financial constraints tissue and blood correlatives 
were not collected, which did not allow characterization 
of ADXS11-001’s ability to activate the innate adaptive 
CD4-positive and CD8-positive T cells within the tumor, 
as well as look at an association between treatment 
responses for ‘responders’ and ‘non-responders’. Profiling 
and quantifying immune-related gene expression in their 
peripheral blood mononuclear cells (PBMCs) before and 
after ADXS11-001 treatment would have been helpful 
to determine whether any gene expression profiles were 
associated with disease control. In addition, evaluating 
changes in the peripheral T-cell repertoire of these 
patients would have helped to determine any association 
with clinical activity. Unfortunately, immunosuppressed 
patients were considered to be ineligible to receive 
ADXS11-001 since it is a live vaccine. 
In conclusion, ADXS11-001 was safe and well-
tolerated. Although the primary outcome was not reached, 
ADXS11-001 may benefit from further evaluation in 
combination for enhanced efficacy of therapy.
MATERIALS AND METHODS
Participants
Eligible patients were at least 18 years of age and 
had confirmed histopathologic diagnosis of squamous 
cell cancer of the anorectal canal that was not amenable 
to curative surgery.  Patients must have: measurable 
disease according to Response Evaluation Criteria in 
Table 3: Safety
Safety Population (n = 36)
Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 Total
Treatment-related Adverse Events, n (%)
Chills 1 (2.8) 21 (58.3) 0 0 0 22 (61.1)
Pyrexia 9 (25.0) 9 (25.0) 0 0 0 18 (50.0)
Nausea 13 (36.1) 4 (11.1) 0 0 0 17 (47.2)
Hypotension 0 12 (33.3) 4 (11.1) 0 0 16 (44.4)
Vomiting 10 (27.8) 3 (8.3) 0 0 0 13 (36.1)
Fatigue 8 (22.2) 4 (11.1) 0 0 0 12 (33.3)
Headache 7 (19.4) 4 (11.1) 0 0 0 11 (30.6)
Infusion-related reaction 0 6 (16.7) 2 (5.6) 0 0 8 (22.2)
Back pain 4 (11.1) 4 (11.1) 0 0 0 8 (22.2)
Diarrhea 2 (5.6) 2 (5.6) 1 (2.8) 0 0 5 (13.9)
Abdominal distension 1 (2.8) 2 (5.6) 0 0 0 3 (8.3)
Cytokine-release syndrome 0 2 (5.6) 1 (2.8) 0 0 3 (8.3)
Decreased appetite 2 (5.6) 1 (2.8) 0 0 0 3 (8.3)
Dizziness 1 (2.8) 2 (5.6) 0 0 0 3 (8.3)
Dyspnea 1 (2.8) 0 2 (5.6) 0 0 3 (8.3)
Serious treatment-related Adverse Events, n (%)
Total Adverse Events 0 2 (5.6) 8 (22.2) 1 (2.8) 0 11 (30.6)
Diarrhea 0 1 (2.8) 1 (2.8) 0 0 2 (5.6)
Hypotension 0 0 2 (5.6) 0 0 2 (5.6)
Ascites 0 0 1 (2.8) 0 0 1 (2.8)
Cytokine-release syndrome 0 0 1 (2.8) 0 0 1 (2.8)
Pneumonia 0 1 (2.8) 0 0 0 1 (2.8)
Infusion-related reaction 0 0 1 (2.8) 0 0 1 (2.8)
Encephalopathy 0 0 1 (2.8) 0 0 1 (2.8)
Acute kidney injury 0 0 1 (2.8) 0 0 1 (2.8)
Respiratory failure 0 0 0 1 (2.8) 0 1 (2.8)
WBC, white blood cell. Shown are treatment-related adverse events by worst grade reported in 3 or more patients and serious treatment-related adverse 
events by worst grade. Data are based on the entire safety population (n = 36).
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Solid Tumors, Version 1.1 (RECIST v1.1) [38]; Eastern 
Cooperative Oncology Group performance status of 0 or 
1; adequate hematologic, hepatic and renal function; and at 
least one prior line of therapy for metastatic/unresectable 
disease. Patients were considered ineligible if they had: 
central nervous system metastases and/or leptomeningeal 
disease; a history of listeriosis or prior ADXS11-001 
therapy; HIV-positive; and a history of autoimmune 
disease requiring steroids or immunosuppressive agents. 
Patients were ineligible if they had: undergone major 
surgery within 6 weeks; received systemic steroid therapy 
and/or immunosuppressive therapy for less than 7 days or 
a live vaccine within 30 days. Patients with a history of 
a second malignancy (excluding basal cell or squamous 
cell carcinoma of the skin, or ductal carcinoma in situ of 
the breast) within 2 years were also ineligible. Implanted 
medical devices (e.g., orthopedic metal based plates) were 
not allowed due to presumed risk for Listeria colonization. 
Study design
This was a Simon two-stage, phase II, open-label, 
multicenter study (NCT02399813). The overall goals of the 
study were to evaluate the efficacy and safety of ADXS11-
001 in patients with persistent/recurrent, loco-regional or 
metastatic SCCA not amenable to curative surgery.
Figure 2: Radiologic progression-free survival in the Efficacy-Evaluable population.
Figure 3: Overall survival in all treated subjects.
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The study was conducted at 8 centers in the United 
States. The study was compliant with International 
Conference on Harmonization Good Clinical Practice 
guidelines for conducting, recording and reporting 
clinical studies [39]. The informed consent form, protocol 
and amendments were submitted and approved by the 
institutional review board or independent ethics committee 
for each respective investigative site. 
Stage 1
During Stage 1, eligible patients received 
intravenous doses of ADXS11-001 (Advaxis, Inc., 
Princeton, NJ, USA) at a dose of 1 × 109 colony-forming 
units (CFU) every 3 weeks (i.e., day 1, 22, and 43) of a 
9-week treatment cycle. Treatment continued for up to 2 
years, until documented disease progression or intolerable 
side effects. Response was evaluated per RECIST v1.1 
[38] and immune-related RECIST (irRECIST) [40] at 
baseline and every 9 weeks thereafter, based on computed 
tomography and/or magnetic resonance imaging results. 
To assess safety, patients were monitored for adverse 
events as per the National Cancer Institute Common 
Toxicity Terminology Criteria for Adverse Events (NCI 
CTCAE v4.03) [41]. 
The study protocol mandated a total enrollment 
of 31 evaluable patients into Stage 1, where evaluability 
was defined as having at least 1 post-baseline response 
assessment. After 31 evaluable patients had been enrolled, 
further accrual was to be temporarily halted to complete 
an interim efficacy analysis. 
Stage 2
If the efficacy results from Stage 1 indicated a 
response rate greater than or equal to 10% (by either 
RECIST v1.1 or irRECIST) or a 6-month PFS rate greater 
than or equal to 20% was observed, an additional 24 
patients were to be enrolled for a total of 55 patients. 
Treatment
At least 30 minutes prior to each ADXS11-001 
infusion, patients completed a prophylactic regimen to 
mitigate and manage potential cytokine release symptoms 
consistent with the mechanism of action of ADXS11-001. 
The regimen consisted of nonsteroidal anti-inflammatory 
drugs (NSAIDs), antihistamines, anti-emetics, and 
H2 receptor antagonists. Additional doses of NSAIDs 
or antiemetics were provided on days 1–2 following 
infusion, if needed. Furthermore, all patients received 
a 7-day course of antibiotic therapy (oral trimethoprim/
sulfamethoxazole or ampicillin for patients with a sulfa 
allergy) starting 72 hours after drug administration to help 
ensure clearance of the attenuated Lm vector. In addition, a 
3-year Lm surveillance period including a 6-month course 
of antibiotics following treatment discontinuation.
Patients were treated with intravenous ADXS11-001 
administered over 60 minutes every 3 weeks at a dose of 
1 × 109 CFU for up to 2 years or until a discontinuation 
criterion is met.  A treatment cycle is defined as 9 weeks. 
Tumor assessments occurred every 9 weeks.
Patients were followed for survival via a phone 
call every 3 months following ADXS11-001 treatment 
discontinuation. The end of the study was to be defined as 
1 year after the last patient had been enrolled. 
Outcomes
The primary efficacy co-endpoints for the study 
were ORR measured by RECIST v1.1 and 6-month PFS 
rate. Secondary efficacy objectives were the duration of 
response, median PFS and overall survival (OS). The 
primary safety endpoint was to characterize the safety 
and tolerability of ADXS11-001 using NCI CTCAE v4.0 
criteria. 
Statistical analyses
The study employed a 2-stage design for testing the 
two primary efficacy measures. The study used Simon’s 
method with null and alternative hypotheses Ho: p ≤ .10 
and Ha: p > .25, whereby p represents the ORR with 
ADXS11-001, and determined that 31 patients needed to 
be enrolled in Stage 1 and an additional 24 patients be 
enrolled in Stage 2 (if 3 or more responses were observed 
in Stage 1). A 2-endpoint, 2-stage decisional framework 
was designed using the Two-Stage approach proposed by 
Benny Zee, et al. [42]: if Stage 1 demonstrates an ORR 
>10% or 6-month PFS > 20%, then enrollment will move 
to Stage 2. Using the Multinomial Two-Stage approach 
proposed by Benny Zee, et al. [42], we simulated 50,000 
trials to examine the Type I and II errors under this design 
assumption. The following estimates, including Type I 
and II errors, from these simulations are: Type I error of 
0.01876 with a probability of stopping early = 0.99; Type 
II power is 0.9277 (See Supplementary Material for more 
detail).
The analysis of the Stage 1 ORR and 6-month PFS 
data was performed on the ORR evaluable population in 
accordance with the protocol-defined requirements to 
determine if either criterion were met to proceed with Stage 
2 enrollment. All primary and secondary analyses were 
also performed with the all enrolled patients. The degree 
of radiographic response was determined by the treating 
investigator. The primary assessment for the interim 
analysis was based on confirmed radiographic responses 
of CR and PR requiring confirmation with a subsequent 
diagnostic imaging study 4–8 weeks later. The 95% CIs 
around proportions were calculated using an exact binomial 
calculation. Kaplan-Meier estimates were generated in 
terms of the median PFS and survival probability at selected 
time points (e.g., 2, 4, 6 and 8 months), along with the 
corresponding 2-sided 95% CIs for the estimates. CIs for 
median OS were based upon the methods of Brookmeyer 
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and Crowley [43]. CIs for survivorship estimates were 
calculated using the Greenwood formula. Disease Control 
Rate (DCR) was summarized descriptively, where DCR 
was defined as the proportion of patients with objective 
evidence of CR, PR or SD. 
All adverse events and serious adverse events were 
summarized for the treatment period and for the 30-day post-
treatment period. Adverse events and serious adverse events 
considered related to study treatment were summarized by 
frequency using descriptive statistics. All data summaries 
and listings were performed using SAS Version 9.2 under 
the Microsoft Windows operating system. 
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